Company Overview and News

 
AHAlife Restructure Update and Appendix 4C Announcement

2017-04-27 marketwired
NEW YORK, NY and SYDNEY, AUSTRALIA--(Marketwired - April 27, 2017) - AHAlife Holdings Limited (ASX: AHL), ("AHA" or "the Company") the online marketplace known for its leadership in the design and lifestyle e-commerce space through curation, today announces its third quarter trading update to accompany the latest Appendix 4C Quarterly Report.
Upvote Downvote

 
AHAlife Restructure and Half Year Results Announcement

2017-02-27 marketwired
NEW YORK, NY and SYDNEY, AUSTRALIA--(Marketwired - February 27, 2017) - AHAlife Holdings Limited (ASX: AHL) ("AHAlife" or "the Company") announced today the appointment of Sebastian Kaufmann as the Company's CEO, effective immediately. Mr Kaufmann has been Chief Curation Officer of AHAlife since the company acquired Kaufmann Mercantile in August 2016.
Upvote Downvote

 
Thanksgiving demonstrates AHL's positive contribution strategy is on track

2016-12-13 marketwired
NEW YORK, NY and SYDNEY, AUSTRALIA--(Marketwired - December 13, 2016) - AHAlife Holdings Limited (ASX: AHL) ("AHA" or the "Company"), a digital marketplace for premium lifestyle products, is pleased to announce a new company record for the highest sales achieved in one day and a positive variable contribution1 from sales over the Thanksgiving weekend.
Upvote Downvote

 
AHAlife Holdings to reveal trading update

2016-10-18 proactiveinvestors.com.au
The halt will remain in place until the opening of trade on Thursday 20th October 2016, or earlier if an announcement is made to the market.
Upvote Downvote

 
CORRECTION -- "AHA to Partner With Equinox"

2016-09-21 marketwired
NEW YORK, NY and SYDNEY, AUSTRALIA--(Marketwired - September 21, 2016) - This document corrects and replaces the news release sent on September 20, 2016 at 9:30 pm ET.
Upvote Downvote

 
KILL - AHAlife Holdings Inc.

2016-09-21 marketwired
NEW YORK, NY and SYDNEY, AUSTRALIA--(Marketwired - September 21, 2016) - Editors and other readers are advised to disregard the news release entitled "Announcement: AHA to Partner With Equinox -- Luxury Fitness Group," issued Tuesday, September 20, by AHAlife Holdings Limited (ASX: AHL). The release was issued in error by the company.
Upvote Downvote

 
AHA Surpasses 1M Users With Acquisition of Kaufmann Mercantile

2016-08-11 marketwired
ACQUISITION AHAlife Holdings Limited (ASX: AHL), AHA (ahalife.com) the online luxury marketplace known for revolutionizing the design and lifestyle e-commerce space through curation, today announces its second acquisition of 2016 with the purchase of the Kaufmann Mercantile (kaufmann-mercantile.com) assets, including users, brands, and website. Kaufmann Mercantile is an online store focused on high-quality products with timeless design, spanning from homewares to accessories, gardening tools and office and kitchen supplies.
Upvote Downvote

 
AHAlife Reviews Milestones and Progress Over First Year as Public Company

2016-06-15 marketwired
NEW YORK, NY and SYDNEY, AUSTRALIA--(Marketwired - June 15, 2016) - AHAlife Holdings Limited (ASX: AHL), the curated marketplace for creative and inspiring objects, today reviewed milestones and progress over the Company's first year as a publicly traded company.
Upvote Downvote

 
Appendix 3B

2016-04-22 asx.com.au
Upvote Downvote

 
Cleansing Notice

2016-04-22 asx.com.au
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

2018-04-25 - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...